Developing a long‑acting small‑molecule ORAI‑1 inhibitor (carboxyamidotriazole) formulated to deliver 6–12 month anti‑angiogenic effects. Targeting treatment of diabetic eye disease and neovascular age‑related macular degeneration to reduce injection frequency.